Cargando…

Correction to: Delivery of oncolytic vaccinia virus by matched allogeneic stem cells overcomes critical innate and adaptive immune barriers

Detalles Bibliográficos
Autores principales:	Draganov, Dobrin D., Santidrian, Antonio F., Minev, Ivelina, Nguyen, Duong, Kilinc, Mehmet Okyay, Petrov, Ivan, Vyalkova, Anna, Lander, Elliot, Berman, Mark, Minev, Boris, Szalay, Aladar A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8489066/ https://www.ncbi.nlm.nih.gov/pubmed/34607595 http://dx.doi.org/10.1186/s12967-021-02866-7

Ejemplares similares

Delivery of oncolytic vaccinia virus by matched allogeneic stem cells overcomes critical innate and adaptive immune barriers
por: Draganov, Dobrin D., et al.
Publicado: (2019)

The ratio of ADSCs to HSC-progenitors in adipose tissue derived SVF may provide the key to predict the outcome of stem-cell therapy
por: Kilinc, Mehmet Okyay, et al.
Publicado: (2018)

First-in-human study of TK-positive oncolytic vaccinia virus delivered by adipose stromal vascular fraction cells
por: Minev, Boris R., et al.
Publicado: (2019)

Colonization of xenograft tumors by oncolytic vaccinia virus (VACV) results in enhanced tumor killing due to the involvement of myeloid cells
por: Kilinc, Mehmet Okyay, et al.
Publicado: (2016)

Development of Allogeneic Stem Cell-Based Platform for Delivery and Potentiation of Oncolytic Virotherapy
por: Nguyen, Duong Hoang, et al.
Publicado: (2022)

Targeting hematologic malignancies with oncolytic vaccinia virus constructs
por: Chen, Nanhai, et al.
Publicado: (2013)

Oncolytic vaccinia virus GLV-1h68 strain shows enhanced replication in human breast cancer stem-like cells in comparison to breast cancer cells
por: Wang, Huiqiang, et al.
Publicado: (2012)

Combination immunotherapy with oncolytic vaccinia virus and checkpoint inhibitor following local tumor irradiation
por: Minev, Boris, et al.
Publicado: (2014)

Canine Adipose-Derived Mesenchymal Stem Cells (cAdMSCs) as a “Trojan Horse” in Vaccinia Virus Mediated Oncolytic Therapy against Canine Soft Tissue Sarcomas
por: Petrov, Ivan, et al.
Publicado: (2020)

Humanized Mice with Subcutaneous Human Solid Tumors for Immune Response Analysis of Vaccinia Virus-Mediated Oncolysis
por: Tsoneva, Desislava, et al.
Publicado: (2017)

Expression of anti-VEGF antibody together with anti-EGFR or anti-FAP enhances tumor regression as a result of vaccinia virotherapy
por: Huang, Ting, et al.
Publicado: (2015)

Intratumoral INF-γ triggers an antiviral state in GL261 tumor cells: a major hurdle to overcome for oncolytic vaccinia virus therapy of cancer
por: Kober, Christina, et al.
Publicado: (2015)

Oncolytic vaccinia therapy of squamous cell carcinoma
por: Yu, Zhenkun, et al.
Publicado: (2009)

Combination treatment with oncolytic Vaccinia virus and cyclophosphamide results in synergistic antitumor effects in human lung adenocarcinoma bearing mice
por: Hofmann, Elisabeth, et al.
Publicado: (2014)

Replication efficiency of oncolytic vaccinia virus in cell cultures prognosticates the virulence and antitumor efficacy in mice
por: Chen, Nanhai G, et al.
Publicado: (2011)

Growth inhibition of different human colorectal cancer xenografts after a single intravenous injection of oncolytic vaccinia virus GLV-1h68
por: Ehrig, Klaas, et al.
Publicado: (2013)

Microglia and astrocytes attenuate the replication of the oncolytic vaccinia virus LIVP 1.1.1 in murine GL261 gliomas by acting as vaccinia virus traps
por: Kober, Christina, et al.
Publicado: (2015)

Vaccinia virus injected human tumors: oncolytic virus efficiency predicted by antigen profiling analysis fitted boolean models
por: Cecil, Alexander, et al.
Publicado: (2019)

Optical Detection and Virotherapy of Live Metastatic Tumor Cells in Body Fluids with Vaccinia Strains
por: Wang, Huiqiang, et al.
Publicado: (2013)

Oncolytic Virotherapy of Canine and Feline Cancer
por: Gentschev, Ivaylo, et al.
Publicado: (2014)

Preclinical Evaluation of Oncolytic Vaccinia Virus for Therapy of Canine Soft Tissue Sarcoma
por: Gentschev, Ivaylo, et al.
Publicado: (2012)

The highly attenuated oncolytic recombinant vaccinia virus GLV-1h68: comparative genomic features and the contribution of F14.5L inactivation
por: Zhang, Qian, et al.
Publicado: (2009)

Virotherapy of Canine Tumors with Oncolytic Vaccinia Virus GLV-1h109 Expressing an Anti-VEGF Single-Chain Antibody
por: Patil, Sandeep S., et al.
Publicado: (2012)

Overcoming tumor immune evasion with an unique arbovirus
por: Lyday, Bruce, et al.
Publicado: (2015)

Preclinical Testing Oncolytic Vaccinia Virus Strain GLV-5b451 Expressing an Anti-VEGF Single-Chain Antibody for Canine Cancer Therapy
por: Adelfinger, Marion, et al.
Publicado: (2015)

Molecular network, pathway, and functional analysis of time-dependent gene changes associated with pancreatic cancer susceptibility to oncolytic vaccinia virotherapy
por: Haddad, Dana, et al.
Publicado: (2016)

Oncolytic Viruses
por: Chen, Nanhai G., et al.
Publicado: (2012)

Significant Growth Inhibition of Canine Mammary Carcinoma Xenografts following Treatment with Oncolytic Vaccinia Virus GLV-1h68
por: Gentschev, Ivaylo, et al.
Publicado: (2010)

Regression of Human Prostate Tumors and Metastases in Nude Mice following Treatment with the Recombinant Oncolytic Vaccinia Virus GLV-1h68
por: Gentschev, Ivaylo, et al.
Publicado: (2010)

Preferential Colonization of Metastases by Oncolytic Vaccinia Virus Strain GLV-1h68 in a Human PC-3 Prostate Cancer Model in Nude Mice
por: Donat, Ulrike, et al.
Publicado: (2012)

Systemic treatment of xenografts with vaccinia virus GLV-1h68 reveals the immunologic facet of oncolytic therapy
por: Worschech, Andrea, et al.
Publicado: (2009)

Permissivity of the NCI-60 cancer cell lines to oncolytic Vaccinia Virus GLV-1h68
por: Ascierto, Maria Libera, et al.
Publicado: (2011)

Imaging Characteristics, Tissue Distribution, and Spread of a Novel Oncolytic Vaccinia Virus Carrying the Human Sodium Iodide Symporter
por: Haddad, Dana, et al.
Publicado: (2012)

Efficient Colonization and Therapy of Human Hepatocellular Carcinoma (HCC) Using the Oncolytic Vaccinia Virus Strain GLV-1h68
por: Gentschev, Ivaylo, et al.
Publicado: (2011)

Evaluation of a New Recombinant Oncolytic Vaccinia Virus Strain GLV-5b451 for Feline Mammary Carcinoma Therapy
por: Adelfinger, Marion, et al.
Publicado: (2014)

Theranostic Potential of Oncolytic Vaccinia Virus
por: Rojas, Juan J, et al.
Publicado: (2012)

Immunotherapeutic Potential of Oncolytic Vaccinia Virus
por: Thorne, Steve H.
Publicado: (2014)

Oncolytic properties of non-vaccinia poxviruses
por: Ricordel, Marine, et al.
Publicado: (2018)

Insertion of the human sodium iodide symporter to facilitate deep tissue imaging does not alter oncolytic or replication capability of a novel vaccinia virus
por: Haddad, Dana, et al.
Publicado: (2011)

The Addition of Recombinant Vaccinia HER2/neu to Oncolytic Vaccinia-GMCSF Given into the Tumor Microenvironment Overcomes MDSC-Mediated Immune Escape and Systemic Anergy
por: de Vries, Christiaan R., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_9k1rbnj7vftfafqd2ucp5usi2g